Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Down 12.0% in March

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 2,210,000 shares, a decrease of 12.0% from the February 29th total of 2,510,000 shares. Currently, 3.3% of the company’s stock are short sold. Based on an average daily volume of 618,500 shares, the days-to-cover ratio is presently 3.6 days.

Integra LifeSciences Stock Down 2.1 %

Shares of Integra LifeSciences stock opened at $34.72 on Tuesday. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. Integra LifeSciences has a twelve month low of $33.24 and a twelve month high of $59.33. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 41.83, a price-to-earnings-growth ratio of 1.07 and a beta of 1.12. The company’s 50 day moving average is $39.18 and its 200 day moving average is $39.65.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. During the same quarter last year, the company posted $0.94 EPS. The firm’s revenue was down .3% compared to the same quarter last year. Research analysts anticipate that Integra LifeSciences will post 3.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. JMP Securities dropped their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. Truist Financial reduced their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. Wells Fargo & Company raised Integra LifeSciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $40.00 to $49.00 in a report on Tuesday, December 5th. Finally, StockNews.com upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Thursday, March 28th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus price target of $45.00.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Swiss National Bank lifted its holdings in Integra LifeSciences by 0.9% during the third quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock valued at $6,187,000 after purchasing an additional 1,500 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Integra LifeSciences in the third quarter valued at about $43,034,000. Bridgefront Capital LLC grew its position in shares of Integra LifeSciences by 299.3% during the second quarter. Bridgefront Capital LLC now owns 16,348 shares of the life sciences company’s stock worth $672,000 after purchasing an additional 12,254 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Integra LifeSciences in the 3rd quarter worth approximately $25,443,000. Finally, Vanguard Group Inc. boosted its stake in Integra LifeSciences by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.